Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,376,787 papers from all fields of science
Search
Sign In
Create Free Account
SK&F 86002
Known as:
SKF 86002
, SKF86002
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
C-Fos Regulation by the MAPK and PKC Pathways in Intervertebral Disc Cells
K. Yokoyama
,
A. Hiyama
,
F. Arai
,
T. Nukaga
,
D. Sakai
,
J. Mochida
PLoS ONE
2013
Corpus ID: 15007286
Background The gene encoding c-fos is an important factor in the pathogenesis of joint disease in patients with osteoarthritis…
Expand
Highly Cited
2008
Highly Cited
2008
Critical role of p38 mitogen-activated protein kinase signaling in septic lung injury*
M. Asaduzzaman
,
Yusheng Wang
,
H. Thorlacius
Critical Care Medicine
2008
Corpus ID: 21779263
Objective: Leukocyte-mediated tissue damage is a key feature in septic lung injury, although the signaling mechanisms behind…
Expand
Highly Cited
2007
Highly Cited
2007
Reactive Oxygen Species and p38 Mitogen-Activated Protein Kinase Activate Bax to Induce Mitochondrial Cytochrome c Release and Apoptosis in Response to Malonate
M. Gomez-Lazaro
,
M. Galindo
,
+6 authors
Joaquín Jordán
Molecular Pharmacology
2007
Corpus ID: 6096098
Malonate, an inhibitor of mitochondrial complex II, is a widely used toxin to study neurodegeneration in Huntington's disease and…
Expand
Highly Cited
2006
Highly Cited
2006
Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling
RM Baldwin
,
M. Garratt-Lalonde
,
Dae Parolin
,
PM Krzyzanowski
,
Maya F. Andrade
,
Iaj Lorimer
Oncogene
2006
Corpus ID: 8070351
Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable…
Expand
Highly Cited
2003
Highly Cited
2003
Role of the p38 MAPK pathway in cisplatin-based therapy
J. H. Losa
,
C. Cobo
,
J. G. Viniegra
,
V. J. S. Lobo
,
S. Y. Cajal
,
R. Sánchez-Prieto
Oncogene
2003
Corpus ID: 2596998
p38 MAPK has been implicated in the response to cancer therapy. To determine whether the activation of p38 MAPK could be specific…
Expand
2003
2003
P38 MAPK: critical molecule in thrombin-induced NF-κB-dependent leukocyte recruitment
J. Kaur
,
R. Woodman
,
P. Kubes
2003
Corpus ID: 13397182
Thrombin-stimulated endothelium synthesizes numerous adhesion molecules to recruit leukocytes; however, it is unknown which…
Expand
Highly Cited
2001
Highly Cited
2001
Role of p38 Mitogen-Activated Protein Kinase in Chemokine-Induced Emigration and Chemotaxis In Vivo1
D. C. Cara
,
J. Kaur
,
M. Forster
,
D. McCafferty
,
P. Kubes
Journal of Immunology
2001
Corpus ID: 6661003
It has been proposed that L-selectin engagement with ligand activates p38 mitogen-activated protein kinase (MAPK) and can impact…
Expand
Highly Cited
2000
Highly Cited
2000
Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1
P. S. Penglis
,
L. Cleland
,
M. Demasi
,
G. Caughey
,
M. James
Journal of Immunology
2000
Corpus ID: 46026659
There is an autocrine relationship between eicosanoid and cytokine synthesis, with the ratio of prostaglandin E2 (PGE2…
Expand
Highly Cited
1995
Highly Cited
1995
Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence.
D. Perregaux
,
D. Dean
,
M. Cronan
,
P. Connelly
,
C. Gabel
Molecular Pharmacology
1995
Corpus ID: 11497143
Cytokine-suppressing anti-inflammatory drugs (CSAIDs) are reported to inhibit production of proinflammatory cytokines such as…
Expand
1994
1994
Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro.
B. Votta
,
D. Bertolini
Bone
1994
Corpus ID: 35167549
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE